Innovation impresario Shields to leave Pfizer

Share this article:
Innovation impresario Shields to leave Pfizer
Innovation impresario Shields to leave Pfizer
Joe Shields, who leveraged a successful career in product marketing into a broader role as Pfizer's director of worldwide innovation, is leaving later this month for medical device firm LifeScan.

Shields will join the Johnson & Johnson operating company's Global Franchise Marketing group. The position will give him the opportunity to influence the development and design of new products and services around the world to help the millions of people suffering from diabetes.

“This role will enable me to participate more fully in the ‘Connected Health' revolution that, among other things, leverages technology to fundamentally change healthcare around the world,” Shields told MM&M. “I am also very excited to learn more about other areas within marketing, particularly new product development, to broaden my experience and skills. Finally, I have a strong personal connection and commitment to improving the quality of life for people with diabetes.”

Shields--who has been in biopharma for 14 years starting with Astra Merck, followed by AstraZeneca and then Pfizer heritage company Wyeth--had been director of worldwide innovation for about six months. He is perhaps best known for his five-year stint as product director of biologic drug Enbrel, which is co-promoted in the US by Pfizer and Amgen. The drug is the top-selling rheumatoid arthritis med in the US and one of the top-selling biotech drugs globally. Shields is also a member of MM&M's editorial advisory board.

Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.